Eurovir

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eurovir

This section provides a factual overview of the medicinal product Eurovir, focusing on its composition, classification, and general purpose.

Property Description
Active ingredient Aciclovir (Acyclovir)
Form Tablet, Capsule, Oral Suspension, Cream, Injectable Solution
Pharmacological class Antiviral Agent / Purine Nucleoside Analogue
General purpose To limit the replication and spread of susceptible viruses
Origin Synthetic Organic Compound

What is Eurovir (Aciclovir) and its Therapeutic Class?

Eurovir is a prescription-only medicinal preparation that contains the widely recognized active substance Aciclovir (also known as Acyclovir). The drug is chemically classified as a Synthetic Purine Nucleoside Analogue, meaning it is manufactured to mimic a natural component of viral DNA.

This classification places the medicine within the high-level group of Antiviral Agents. Its established role is clinically recognized for selectively managing viral proliferation, leading to its inclusion on the WHO List of Essential Medicines and defining its purpose as targeting viruses rather than bacteria.

Compositional Identity and Forms

Eurovir is a single-component product, relying solely on Aciclovir for its therapeutic activity, combined with pharmaceutical excipients. The active ingredient's profile allows for versatility in patient care across multiple formats.

The medication is manufactured in several distinct dosage forms for different routes of administration, including oral forms such as the tablet, capsule, and oral suspension for systemic delivery. Additionally, specialized forms like the topical cream or ointment are available for localized application, alongside the sterile injectable solution for intravenous administration.

General Purpose of a Selective Antiviral Agent

The general purpose of Eurovir is to support the body in managing viral infections by selectively preventing the virus from replicating. This action is rooted in the drug’s characteristic selective toxicity.

This selectivity focuses the medicinal effect directly on the pathogen. The drug achieves its goal by interrupting the virus's ability to copy its own genetic material through a process called DNA chain termination, which consequently helps to reduce the overall viral load and supports the body in limiting the duration and extent of the viral activity.

Regulatory References

  1. WHO List of Essential Medicines
  2. NIH StatPearls: Acyclovir

What side effects are possible with Eurovir?

Possible Side Effects and Safety Information

The safety profile of Eurovir (Aciclovir) is officially organized by the frequency and the physiological system affected, following regulatory standards to classify adverse reactions.

Frequency-Classified Adverse Reactions

The following high-level categorization reflects the incidence rates documented in official regulatory prescribing information:

  • Common Reactions: Include effects such as headache, dizziness, nausea, vomiting, abdominal pain, fever, and certain rashes.
  • Uncommon Reactions: May include hives (urticaria) and reported hair loss (alopecia).
  • Rare Reactions: Are those such as anaphylaxis, angioedema, and reversible increases in liver enzymes or blood urea/creatinine.
  • Very Rare Reactions: Include potentially serious effects like acute renal failure, hepatitis, jaundice, and disturbances of the blood cell counts (e.g., anemia, leukopenia).

Systemic Safety Considerations

The official labeling notes that adverse effects can involve several System-Organ Classes. Effects on the Nervous System may include agitation, confusion, tremor, hallucinations, and seizures, with Acute Renal Failure being a documented, though rare, serious outcome. Severe Dermatological Reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are officially listed.

Population-Specific Safety Notes

The regulatory documentation highlights specific safety considerations for certain patient groups. Older adults may be more susceptible to central nervous system effects, such as confusion or dizziness, due to possible reduced kidney function. Patients with pre-existing renal impairment are at a heightened risk for systemic side effects, which may require monitoring. The risk of Thrombotic Thrombocytopenia Purpura/Hemolytic Uremic Syndrome (TTP/HUS) is specifically noted in the severely immunocompromised patient population.

Overdose and Emergency Response

Overdose and when to seek help

Systemic overdose with the active substance in Eurovir (Aciclovir) is officially documented to primarily affect the central nervous system (CNS) and the renal system.

CNS manifestations may range from confusion, agitation, hallucinations, and somnolence (drowsiness) to severe, life-threatening outcomes such as seizures and coma. Gastrointestinal effects, including nausea, vomiting, and diarrhoea, may also be documented presentations.

A critical, officially stated risk is the development of acute renal toxicity due to the precipitation of Aciclovir crystals in the kidney tubules (crystalluria), which can progress to acute renal failure. This outcome is notably increased in older individuals and patients with pre-existing kidney impairment, where drug clearance is reduced.

Immediate Medical Action Required

In cases of suspected systemic overdose, immediate medical attention must be sought due to the potential for severe CNS and renal failure. Regulatory guidance mandates contacting emergency services for such severe manifestations.

No specific antidote is known for Aciclovir. Management relies on providing general symptomatic and supportive treatment. For severe toxicity, haemodialysis is an officially recognized procedural intervention documented for significantly removing the drug from the circulation.

Therapeutic Uses of Eurovir

What Eurovir Treats: Main Uses and Benefits

Eurovir (Aciclovir) is commonly used across conditions presenting with acute or disruptive episodes caused by the Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV). It is considered relevant when supportive symptom management is appropriate, as it supports the patient during difficult episodes by easing distress and contributing to improved comfort.

The medication is applied across therapeutic domains for easing challenging symptoms of cold sores, genital herpes, shingles (Herpes Zoster), and chickenpox (Varicella). It is also relevant in critical contexts like Herpes Simplex Encephalitis and for providing long-term suppressive support against frequent recurrences, especially in immunocompromised patients.

As a patient-oriented benefit, Eurovir may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Pain and Discomfort

Eurovir is relevant for easing symptoms that interfere with daily comfort, such as burning, tingling, and pain related to viral lesions. It provides support that helps ease the overall symptom burden during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Eurovir?

Eurovir (Aciclovir) eligibility is strictly defined by regulatory authorities based on a patient’s health status and age.

The medicine is contraindicated and must not be used by any individual with a documented hypersensitivity or severe allergic reaction to Aciclovir, its related compound Valacyclovir, or any other ingredient within the specific formulation.

Eligibility is conditional for certain populations where the body's ability to process the drug is altered. Patients with impaired renal function require a restricted use status, as the drug’s clearance depends heavily on the kidneys, necessitating professional dose adjustment. Older adults may also require special consideration and possible dose reduction due to age-related decline in kidney function.

For age-related use, the medicine is established for adults and certain older children. However, the safety and effectiveness of formulations like the topical cream are not established for pediatric patients under the age of 12.

Use during pregnancy and breastfeeding is also conditional. Official labeling states that the medicine should only be used if the potential benefit to the mother significantly outweighs the potential unknown risks to the fetus or nursing infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Information (Official Regulatory Statements)
Specific Interacting Medicines Probenecid, Cimetidine, Mycophenolate Mofetil (inactive metabolite), Theophylline.
Mechanistic Basis Competition for active renal tubular secretion, leading to reduced clearance and increased plasma concentrations (AUC).
Interaction-Related Restriction Co-administration with other potentially nephrotoxic agents requires caution due to an officially increased risk of renal dysfunction.

The official regulatory profile for Eurovir (Aciclovir) is predominantly defined by its elimination via active renal tubular secretion. Co-administration of medicines that share this pathway, such as Probenecid and Cimetidine, results in a documented reduction in Aciclovir’s renal clearance and a subsequent increase in its plasma concentrations. Similarly, increases in the plasma levels of both Aciclovir and the inactive metabolite of Mycophenolate Mofetil have been reported when co-administered.

Separately, an experimental study noted that concomitant therapy with Aciclovir increases the plasma exposure (AUC) of Theophylline. The risk of renal impairment is officially increased by co-use with other potentially nephrotoxic drugs, a caution particularly relevant for elderly patients. Oral absorption of Aciclovir is not significantly affected by food, according to regulatory documentation.

Mechanism of Action

The mechanism of Eurovir (Aciclovir) is defined by its selective interference with the pathogen's genetic code, utilizing a specific two-step process. This process begins with selective activation, where the inactive drug is phosphorylated almost exclusively by the viral enzyme Thymidine Kinase (TK), which is synthesized only within infected cells. The physiological consequence of this reliance on a pathogen-specific enzyme is a selective mechanism that limits the drug's functional scope primarily to infected cells.

Once fully activated to Aciclovir Triphosphate, the molecule acts as a false building block that is incorporated into the growing viral DNA strand by Viral DNA Polymerase. Because the incorporated drug lacks the necessary structure for the next genetic base to attach, the entire DNA copying process irreversibly stops—an event known as DNA chain termination. This interruption halts the creation of new viral genetic material, resulting in a reduction in the systemic viral load.

The drug's action is strictly dependent on the active replication state of the virus for the production of the viral TK enzyme. Consequently, the mechanism is functionally ineffective against the virus while it is dormant, or latent, within the host's nerve cells.

Dosage and Administration Information

Eurovir (Aciclovir) administration is structured by specific routes, dosage schedules, and procedural requirements. The medicine is administered via three primary routes: oral (using tablets, capsules, or suspension), intravenous (IV) infusion, and topical (using creams or ointments). The selection of the route is based on the required speed and extent of systemic absorption.

Dosage Patterns and Frequency

Dosing protocols differentiate between short-term acute treatment and long-term suppressive use. Treatment of an acute episode often necessitates frequent administration, commonly five times daily, using doses that typically range from 200 mg up to 800 mg per dose. Conversely, long-term suppressive regimens usually follow a twice daily schedule, which may extend for up to 12 months before reassessment.

Oral forms may be taken with or without food, though patients are generally instructed to maintain adequate hydration during the course of use. If a dose is missed, it is generally advised to take it immediately unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; doses should never be doubled.

Procedural and Population Constraints

The intravenous route requires strict procedural adherence: the injectable solution must be diluted to a specific concentration and administered as a slow infusion lasting at least one hour. Rapid or bolus injection is not an approved administration method. Furthermore, standard protocols involve dose adjustments for certain populations. Patients with impaired kidney function require a reduced dose or an extended interval between administrations to prevent accumulation, a consideration that also applies to older adults whose renal clearance may be diminished.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eurovir (Aciclovir)

This overview describes the types of research and clinical studies that have been conducted to evaluate Eurovir (Aciclovir), focusing on what was studied and what the research findings suggest, according to regulatory and scientific documentation. This is not medical advice or treatment guidance.


Evidence for Use in Genital Herpes (Acute Episodes and Suppression)

Research exploring this medicine for genital herpes involved short-term Randomized Controlled Trials (RCTs) for acute episodes and longer-term RCTs for continuous use (suppressive therapy). Studies monitored outcomes related to physical discomfort, such as pain and tingling, and outcomes describing episodic changes, like lesion healing time. The research was evaluated in both immunocompetent adults and specific populations with underlying immune conditions.

Findings describe patterns observed in studies where treatment reported measurements of a difference in the duration of healing and symptoms compared to non-treatment groups. For suppressive studies, research highlights a change measured over long-term study periods, reporting a difference in the frequency of symptomatic outbreaks.

Evidence for Severe, Systemic Viral Infections

Research has also examined the use of Eurovir for managing critical, life-threatening conditions, such as Herpes Simplex Encephalitis (HSE) and severe, disseminated infections. The research involves controlled clinical studies and registry data, rather than large-scale placebo-controlled trials. The studies monitored outcomes related to functional imbalance, specifically rates of patient outcomes and measures of neurological status.

Findings describe patterns observed in the studies related to patient outcomes when compared to historical data before the medicine was available. The research indicates that outcomes linked to functional status were related to the speed of treatment initiation following presentation of symptoms.

What Research Gaps and Uncertainty Remain

Despite comprehensive research, some areas of uncertainty remain. For shingles, findings were mixed regarding the ability of the medicine to prevent the occurrence of long-term pain (Postherpetic Neuralgia, or PHN), meaning certainty remains low regarding this specific outcome. Additionally, there is limited information for long-term outcomes extending over multiple years of continuous use, and data for certain subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Eurovir (FAQ)


Q: How is Eurovir generally described as being different from other similar medicines for the same condition?

A: Official product information states that Aciclovir is a synthetic antiviral drug designed to stop the herpes virus from multiplying. Its related medicine, Valaciclovir, is a 'prodrug'—meaning it converts into Aciclovir inside the body. This conversion results in Valaciclovir achieving higher systemic exposure, which allows for different dosing schedules compared to Aciclovir.


Q: Is it normal to feel tired or fatigued after starting Eurovir?

A: According to official reports, side effects such as fatigue and tiredness have been documented during the clinical use of Aciclovir.


Q: Does Eurovir cause any known long-term or irreversible health issues?

A: Aciclovir is typically used for specific treatment durations. Official drug information notes that rare, severe adverse events—such as acute kidney failure or specific blood disorders (like TTP/HUS in certain populations)—have been documented.


Q: Does Eurovir interact with common over-the-counter pain medications like ibuprofen or paracetamol?

A: Official patient guidance indicates that Paracetamol is generally safe to take with Aciclovir. However, some common pain relief medications belong to a class of drugs that may affect the kidneys. Combining these with Aciclovir may be associated with an increased risk of kidney-related side effects.


Q: How long does it typically take to feel the initial beneficial effects of Eurovir?

A: Clinical studies indicate that the viral inhibition begins quickly. Research suggests measurable clinical effects, such as a reduction in new lesions and accelerated pain relief, are observed within the first few days of treatment.


Q: Can Eurovir be safely prescribed to children?

A: Yes, Aciclovir is used to treat children, including infants. The dose for children is carefully determined based on their body weight, age, and the specific condition being treated.


Q: Are there specific medical conditions that generally prevent someone from using Eurovir? / Why is Eurovir sometimes not recommended for people with severe liver or kidney problems?

A: The primary regulatory contraindication is a known allergy to Aciclovir or Valaciclovir. Since the body mostly eliminates the drug through the kidneys, patients with kidney impairment require careful monitoring and an adjusted dose. Caution is also noted in patients with severe liver disease.


Q: Is Eurovir available in different strengths, and what determines the strength prescribed?

A: Yes, Aciclovir is available in several strengths (like 200 mg, 400 mg, and 800 mg tablets) and as a liquid suspension. Official product information indicates that the strength used is generally guided by factors such as the specific illness being treated, the patient’s age, and considerations regarding kidney function.


Q: What is the general advice about the best time of day to take Eurovir (e.g., morning or evening)?

A: Official instructions emphasize that doses must be taken at evenly spaced intervals throughout the day and night. This scheduling is used to help maintain consistent levels of the drug in the body, which supports its therapeutic activity. The exact timing depends on the frequency of doses prescribed.


Q: Can Eurovir be used by people with a history of allergic reactions to other drugs?

A: The primary regulatory contraindication is a known allergy to Aciclovir or its related medicine, Valaciclovir. Patients with a known history of allergic reactions to any other medication should always inform their prescribing professional, as this history is relevant to the individual risk assessment.


Q: What is the difference between Eurovir tablets and liquid formulations?

A: Aciclovir is available in both tablet form and as an oral suspension (liquid). The liquid form is commonly used for children or for patients who have trouble swallowing. Official information also notes that the tablets can be dissolved in a small amount of water if swallowing is difficult.


Q: Do the side effects of Eurovir usually go away quickly after stopping the medicine?

A: Regulatory safety information indicates that many of the commonly reported side effects, such as headache or nausea, are mild and transient. These effects usually resolve as the body adjusts to the medicine, or they subside after the treatment course is complete.


Q: Is there any non-directive information about how to potentially reduce the chance of side effects?

A: Official patient leaflet information highlights the importance of maintaining adequate hydration and drinking plenty of fluids while taking Aciclovir. This action is intended to help reduce the potential risk of kidney-related side effects.


Q: Can I take Eurovir if I am also taking vitamins or herbal supplements?

A: Official guidance states that there is limited information on the safety of combining Aciclovir with herbal remedies or supplements, as these products are generally not tested in the same way as prescription medicines. Official information reminds patients that all supplements being taken should be communicated to a healthcare professional.


Q: Will Eurovir interact with birth control pills?

A: Regulatory and drug interaction data have generally not reported a clinically significant interaction between Aciclovir and common hormonal birth control pills.


Q: If I stop taking Eurovir early, what are the general risks described in official sources?

A: Regulatory documents indicate that prematurely stopping the medicine carries the risk of incomplete viral suppression. This action may be associated with incomplete treatment, prolonged symptoms, or the potential for viral resistance.


Q: Is Eurovir considered a new medication, or has it been available for a long time?

A: Aciclovir is not a new medication; it is considered well-established. Official drug history records show that the active ingredient was originally granted FDA approval in 1982.


Q: Can you drink alcohol in moderation while taking Eurovir?

A: Official information does not report a direct, clinically significant interaction between Aciclovir and alcohol. However, because alcohol may increase the occurrence of side effects such as dizziness or fatigue, limiting consumption is often suggested in patient guidance.

How should Eurovir be stored and disposed of?

Storage and Handling

Official regulatory documents define strict storage conditions for Eurovir (aciclovir) depending on its form:

  • Temperature: Most formulations, including the oral suspension and concentrate for infusion, must not be stored above 25°C.
  • Environmental Protection: The concentrate for infusion must be kept in the original carton to protect from light. Liquid forms, including the oral suspension and concentrate, must not be refrigerated or frozen, as this may cause product instability or precipitation.
  • Stability: The oral suspension must be discarded 30 days after first opening. The diluted solution for infusion has a documented stability of up to 12 hours at 25°C and should be used immediately after preparation.

Child Safety and Disposal

All forms must be stored out of the sight and reach of children, as required by regulatory labeling. Any unused or expired medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eurovir found in:

A-Z Index: